Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: The EPIC study

Autor: Kay-Thee Khaw, Silvia Polidoro, Elio Riboli, Antonio Agudo, Graham Byrnes, Isabelle Romieu, Raul Zamora-Ros, Jana Foerster, Eleni-Maria Papatesta, Giovanna Tagliabue, Kaja Tikk, Antonia Trichopoulou, Marie-Christine Boutron-Ruault, Jonas Manjer, Jytte Halkjær, Elisabete Weiderpass, Eiliv Lund, Aurelio Barricarte, Anne Tjønneland, Maria Sandström, Heiner Boeing, Nerea Larrañaga, Konstantinos K. Tsilidis, Salvatore Panico, Dimitrios Trichopoulos, Julie A. Schmidt, Agnès Fournier, Carine Biessy, Joakim Hennings, Rosario Tumino, Esther Molina-Montes, Nicholas J. Wareham, Marc J. Gunter, Sabina Rinaldi, Renée T. Fortner, Petra H.M. Peeters, Martin Almquist, Silvia Franceschi, Marcial Argueelles, Carmen Navarro, Sylvie Mesrine, Giovanna Masala, Hendrik B. Bueno-de-Mesquita
Rok vydání: 2014
Předmět:
Zdroj: International Journal of Cancer. 136:1218-1227
ISSN: 0020-7136
Popis: Differentiated thyroid carcinoma (TC) is threefold more common in women than in men and, therefore, a role of female hormones in the etiology of differentiated TC has been suggested. We assessed these hypotheses in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Among 345,157 women (mean age 51) followed for an average of 11 years, 508 differentiated TC cases were identified. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. No significant associations were observed between differentiated TC risk and number of pregnancies, breast feeding, menopausal status, and age at menarche and at menopause. Significant associations were found with history of infertility problems (HR 1.70; 95% CI 1.12-2.60), a recent pregnancy (HR for 5 vs. >5 years before recruitment 3.87; 95% CI 1.43-10.46), menopause type (HR for surgical vs. natural menopause: 2.16; 95% CI 1.41-3.31), oral contraceptive (OC) use at recruitment (HR: 0.48; 95% CI 0.25-0.92) and duration of OC use (HR for 9 vs. 1 year: 0.66; 95% CI: 0.50-0.89). An increased risk was also found with hormone replacement therapy use at recruitment (HR=1.30, 95% CI 1.02-1.67), but this was not significant after adjustment for type of menopause (HR=1.22, 95% CI 0.95-1.57). Overall, our findings do not support a strong role of reproductive and menstrual factors, and female hormone use in the etiology of differentiated TC. The few observed associations may be real or accounted for by increased surveillance in women who had infertility problems, recent pregnancies or underwent surgical menopause.
Databáze: OpenAIRE